A Neuren study of trofinetide, also known as NNZ-2566, for females with Rett Syndrome

Investigators / Sponsors


This clinical study is sponsored by Neuren Pharmaceuticals Limited, a public biopharmaceutical company developing new therapies for brain injuries, neurodevelopmental and neurodegenerative disorders. Current trials target chronic conditions such as Rett and Fragile X syndromes as well as acute neurological injuries.

For more information on Neuren Pharmaceuticals, visit

The study is partially funded by, a 501c(3) non-profit corporation whose mission is to accelerate full spectrum research to cure Rett syndrome and empower families with knowledge and connectivity.

For more information on, visit